UK biomaterial company BioInteractions is re-launching its most Advanced Antithrombogenic Coating, Astute, at COMPAMED. A non-leaching active antithrombogenic coating, Astute is being targeted at procedures including heart valve replacements, haemodialysis, neurological implants, and oxygenators where the implant is required to stay in the body for long periods of time.
Shutterstock / Kolomiiets Iryna
Thanks to its clinical recognition for being safe to use on Class III blood contacting medical devices, BioInteractions is providing Astute as an answer to serious issues including increasing healthcare associated infections (HAIs) and medical device rejection.
Every year millions of people have regained health because of a medical device implanted in their body. From hip joints to heart valves, these devices represent $90.5 billion to the global economic market according to industry researchers, and that number is expected to grow as technology improves and the population ages. It is a major concern of the medical industry that human bodies frequently reject implanted devices, and there are no consistently effective strategies to prevent or suppress it. Alongside this issue, over half of the nearly two million HAIs can be attributed to indwelling medical devices. This makes the requirement for implants that can last a lifetime in people’s bodies even more critical, not only to help resolve these issues but also increase patient safety.
Astute has been developed to improve the hemocompatibility of a device surface by mimicking the endothelial layer. The coating has obtained clinical recognition for its safe and successful use on Class 3 blood contacting medical devices for over 30 years. The multi-action technology confronts clot formation on devices to provide state-of-the-art biocompatibility and antithrombogenicity over long periods of time. Astute contains an active component that interrupts the blood cascade mechanism, preventing platelets from activating and hinders thrombus formation. This ensures the blood remains inactive and does not clot further along in the patient. The coating combines this with passive non-thrombogenic elements to prevent deposition and adhesion on the device surface, enhancing the overall antithrombogenic efficacy. Astute uses only non-leaching components, which reduces patient risk and helps the coating to continue performing without reduction in performance over time.
Arjun Luthra, BioInteractions’ commercial director, said: “We understand the significant risks of both device rejection and increasing HAIs to patient safety, which is why we have worked very hard to develop our non-leaching, antithrombogenic coating solution Astute. Thanks to advances in terms of Astute’s platelet adhesion (prevents 95% of platelet formation) and platelet activation (halts blood cascade mechanism by 92%), we have achieved results of more than 98% reduction in blood clot formation. What this all means is that we have a coating solution that when implemented on an indwelling device, turns it into a permanent implant that never needs to be replaced, therefore reducing the need for further surgeries and ultimately, improving patient safety.”
BioInteractions will be at Compamed, Hall 8B, stand number N20 on 13-16 November showcasing Astute alongside its current portfolio of biocompatible technology solutions including Assist and TridAnt.
